This study is significant in that we demonstrated that MYP treatment improved all major symptoms related to ME/CFS, such as depression, pain, and fatigue behavior, and that detailed mechanisms were induced through the brain and intestines. This evidence concerns the gene NOL3 and depressive disorder.